However, few studies have investigated the effect of ERCC1, RRM1 and β-tubulin III(TUBB3) expression on the clinical outcome of NSCLC or the association between ERCC1, RRM1 and TUBB3 and clinical characteristics.12,13 In the current study, we aimed to analyze the expression of ERCC1, RRM1 and TUBB3 in 305 patients with advanced NSCLC, and investigated whether these genes can be used as biomarkers for predicting tumor response and clinical outcome. This evidence concerns the gene TUBB3 and neoplasm.